Real-world burden of comorbidities in US patients with psoriasis - 14/12/17
, Lillian Mellars, MS b, Arun Changolkar, PhD a, Steven R. Feldman, MD, PhD cAbstract |
Background |
Understanding background comorbidity rates in psoriasis can provide perspective for adverse events associated with new therapies.
Objective |
We sought to assess the extent of comorbidities in psoriasis patients by use of the Truven Health Analytics MarketScan database.
Methods |
MarketScan, comprising commercial claims representative of a large US-insured population, had 1.22 million patients with ≥1 claim with a psoriasis diagnosis between January 1, 2008, and December 31, 2014. Patients ≥18 years of age who had ≥2 health claims in any diagnosis field for psoriasis (International Classification of Diseases, 9th Revision, Clinical Modification 696.1) with a psoriasis diagnosis (index) date between July 1, 2008, and June 30, 2014, were included to allow follow-up observation time.
Results |
Prevalence and incidence of 24 comorbidities were assessed in 469,097 psoriasis patients; the most common comorbidities were hyperlipidemia (45.64% and 30.83%, respectively), hypertension (42.19% and 24.19%), depression (17.91% and 12.68%), type 2 diabetes mellitus (17.45% and 8.44%), and obesity (14.38% and 11.57%).
Limitations |
A limitation of the study was that only a certain insured population was represented.
Conclusions |
Comorbidity rates align with those described in the literature and support the concept that psoriasis patients have high rates of cardiometabolic comorbidities. This analysis highlights the potential utility of very large insurance databases for determining comorbidity prevalence in psoriasis, which may aid health care providers in managing psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : comorbidity, database, disease burden, MarketScan, medical insurance claims, psoriasis
Abbreviations used : CI, ICD-9-CM, MI, THIN
Plan
| This study was sponsored by Celgene Corporation. The authors received editorial support in the preparation of the manuscript from Peloton Advantage, LLC, funded by Celgene Corporation. The authors, however, wrote, directed, and are fully responsible for all content and editorial decisions related to the development of the manuscript. |
|
| Conflicts of interest: Dr Shah was an employee of Celgene Corporation at the time of study conduct and has access to stocks, stock options, and restricted stock units in Celgene Corporation. Ms Mellars and Dr Changolkar were contractors employed by Celgene Corporation at the time the study was conducted. Dr Feldman has served as a consultant to AbbVie, Amgen, Baxter, Celgene Corporation, Cosmederm, Eli Lilly, Galderma, GSK, Hanall Pharmaceutical, Kikaku, LEO Pharma, Merck, Merz Pharmaceuticals, Mylan, Novartis, Pfizer, Qurient, Stiefel/GSK, Suncare Research, and Xenoport; has served as a speaker for AbbVie, Celgene Corporation, Janssen, LEO Pharma, Mylan, Novartis, Stiefel/GSK, and Taro; received grant support from AbbVie, Amgen, Anacor, Celgene Corporation, Galderma, Janssen, Novartis, Pfizer, Qurient, and Stiefel/GSK; and served on advisory boards for Boehringer Ingelheim, Pfizer, and Xenoport. |
|
| Reprints not available from the authors. |
Vol 77 - N° 2
P. 287 - août 2017 Retour au numéro
Article précédent
- Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis
- Jacob P. Thyssen, Peter B. Toft, Anne-Sofie Halling-Overgaard, Gunnar H. Gislason, Lone Skov, Alexander Egeberg
- The risk of malignancy among biologic-naïve pediatric psoriasis patients: A retrospective cohort study in a US claims database
- Yun Gu, Beth L. Nordstrom
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?